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HIGH TITER TRANSIENT GENE EXPRESSION PLATFORM BASED ON GS CHO CELL LINE – RAPID
PROTEIN EXPRESSION TOOL FOR PRECLINICAL DRUG DEVELOPMENT
Yashas Rajendra, Biotechnology Discovery Research, Eli Lilly and Company
rajendra_yashas@lilly.com
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Most of the high yielding transient gene expression (TGE) methods for CHO cells reported in the literature
involve extensive cell line engineering and plasmid vector optimization in addition to long fed batch cultures
lasting up to 21 days. However, this is a laborious, time intensive process and also requires specific vector
engineering for transient expression. Here, we present results from development of a high titer TGE process
based on GS-CHO cells without resorting to host cell line engineering or TGE specific vector engineering. This
was achieved by optimization of direct addition of DNA and PEI, use of DMA to enhance transgene mRNA
levels and addition of a proprietary feeds. Protein titers of up to 0.35 g/L or 1 g/L were reached in a 7 day or a
16 day bioprocess respectively. Robustness and reproducibility of this method was demonstrated at scales
ranging from 2 ml to 2 L. Moreover, these transfections could be performed in a high throughput manner in 24
deep well plates. Taking advantage of this, we coupled this high throughput transfection process to a highthroughput semi-automated Protein A purification process capable of purifying up to 72 unique mAbs
simultaneously. We designed a variable volume elution strategy based on supernatant titer and were able to
obtain protein yields of 0.25 mg to 1 mg at concentration >0.5 mg/ml. In efforts to further increase protein
expression levels, we tested co-transfection of proteins involved in the unfolded protein response with the goal
to enhance secretion capabilities of the transfected cell population. We identified that co-transfection of plasmid
DNA encoding XBP1S increased protein expression by 15% to 80%. We also present case studies comparing
product quality attributes from transient HEK293, transient CHO and stable CHO pool. Overall, our results
demonstrate that a high yielding and representative transient CHO process can be developed while maintaining
the speed and simplicity of a TGE process.

